Evolus

EVOLUS INC

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

wall street chart shutter2

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

New Oriental Education & Technology Group

EOLS

FTAI

GOEV

HSDT

REPL

SCHW

Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates

Crude-oil-4-logo

Crude Oil Down 2%; D.R. Horton Earnings Top Views

Top 3 Charles Schwab Index Funds To Boost Your Investment Portfolio

Movers

ACHR

LUNR

MRNA

OKLO

RGTI

RKLB

VSAT

Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday

Evolus Inc

Press Releases

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Arvinas

BGM Group

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

GH Research

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Harrow

Indivior

Innoviva

Maze Therapeutics

Nuvation Bio

Ocular Therapeutix

Omeros

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

SIGA Technologies

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Tilray Brands

Trevi Therapeutics

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zevra Therapeutics

Barclays

HC Wainwright & Co.

Needham

Stifel

Mizuho

Comments

Evolus

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga